Material Agreement Form 8 K

Item 1.01. Entry into a Material Definitive Agreement.

Alimera Sciences, Inc. (the "Company") entered into as of July 17, 2024, a Manufacturing Services Agreement (the "New Siegfried Agreement") with Alliance Medical Products, Inc. d.b.a. Siegfried Irvine ("Siegfried") that supersedes and replaces the First Amended and Restated Commercial Contract Manufacturing Agreement, dated as of February 5, 2016, between the Company and Siegfried.

Pursuant to the terms of the New Siegfried Agreement, Siegfried will be responsible for manufacturing and supplying to Alimera agreed-upon quantities of ILUVIEN® at certain cost plus amounts, subject to adjustments set forth in the New Siegfried Agreement.

Siegfried has agreed that during the term of the New Siegfried Agreement, it will not manufacture for any other customer any product competitive with ILUVIEN® (meaning any other drug-eluting eye implant for the treatment of diabetic macular edema or uveitis).

The term of the New Siegfried Agreement is for a period of five (5) years and shall thereafter automatically renew for successive two (2) year terms unless either party provides notice of non-renewal to the other party within a specified period of time prior to the beginning of the next automatic renewal term.

The New Siegfried Agreement contains customary representations and warranties. The assertions embodied in the representations and warrants were made solely for purposes of the transaction contemplated therein and may be subject to important qualifications and limitations. Moreover, the representations and warranties may be subject to a contractual standard of materiality that may be different from what may be viewed as material to stockholders or may have been used for purposes of allocating risk between the Company and Siegfried rather than establishing matters as facts. For the foregoing reasons, no person should rely on such representations and warranties as statements of factual information at the time they were made or otherwise.

A copy of the New Siegfried Agreement will be filed as an exhibit to the Company's Form 10-Q for the quarter ended June 30, 2024. The foregoing description of the terms of the New Siegfried Agreement is qualified in its entirety by reference to the full text of such exhibit.